AAO 2024: New gene therapy shows promise for treatment of …
2024年10月20日 · Key Takeaways. MCO-010 gene therapy improves vision in retinitis pigmentosa patients, with up to 50% gaining significant visual acuity. The therapy is mutation-agnostic, targeting a range of genetic mutations, unlike Luxturna, which is …
Ophthalmology Times - Ophthalmology news, articles, and events
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
AAO 2024: Long-term low-dose antiviral treatment benefits …
2024年10月19日 · Long-term, low-dose antiviral treatment reduces the risk for potentially vision-damaging bouts of inflammation and infection, as well as pain, which occur when shingles affect the eye, according to new research presented October 19 at the American Academy of Ophthalmology’s (AAO) annual meeting in Chicago.
What your patients need to know about eye color-changing drops
2024年8月28日 · The American Academy of Ophthalmology indicates that consumers who may see the eye color-changing drops advertised and used on TikTok or elsewhere online should be advised that they are not FDA approved.
Johnson & Johnson launches TECNIS Odyssey IOL in US
2024年10月1日 · Johnson & Johnson is expanding the launch of its presbyopia-correcting intraocular lense (IOL), TECNIS Odyssey, in the US.. The TECNIS Odyssey IOL is a new full vision range IOL, built on the TECNIS platform from Johnson & Johnson, which according to the company provides two times better contrast in low lighting than PanOptix. 1 Peter Menziuso, company group chairman, Vision, Johnson & Johnson ...
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
2024年10月14日 · Key Takeaways. enVista Envy IOLs provide a continuous range of vision with high dysphotopsia tolerance, enhancing cataract surgery outcomes. U.S. and Canadian trials showed high patient satisfaction, with minimal issues related to glare and close object viewing.
New canalicular gel shows promise for dry eye treatment
2024年11月13日 · Reviewed by Mark Packer, MD; and Eric Donnenfeld, MD. In June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has shown it to be a safe, well-tolerated, and effective treatment for dry eye. 1 This device offers a new option for managing a condition that affects millions of patients.. A study, led by first author Mark Packer, MD ...
Ophthalmologists: Castor oil shouldn’t be rubbed in the eyes, no …
2023年8月8日 · Ophthalmologists are issuing a warning not to use castor oil as a way to treat vision problems amid claims circulating on TikTok. In its heyday, castor oil was considered a jack-of-all-trades home remedy, used as a laxative, a moisturizer and even as a …
Understanding cerebral/cortical visual impairment: New insights …
2024年11月22日 · Cerebral/cortical visual impairment (CVI) is a leading cause of childhood blindness, caused by brain damage to visual pathways. Researchers are refining its definition and diagnostic methods to improve early detection and treatment, enhancing outcomes for …
AAO 2024: Livionex reports positive end-of-phase 2 meeting with …
2024年10月18日 · According to the company, there are no FDA-approved pharmacological therapies for age-related cataracts. Its C-KAD eye drop, improves vision in patients with early-to-moderate cataracts, by penetrating the eye to reduce lens clouding, the main cause for cataracts.